Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis

Table 1 Model parameters inputs

Adverse events							Source
	GI discomforts	Symptomatic ulcer	Complicated GI	Stroke	MI	HF	Source
Cost ($)^a
Initial states	10.52 + cost of medication of OA	34.57	1354.15	1289.92	5190.93	1182.33	SuValue Database (Additional fie 1: Table S4-5)
Post states	–	0.81^b	21.54^b	619.59	948.47	451.29	[13]
Utility weights for AEs (1 = OA patients without any AEs)
Initial states	0.73	0.55	0.46	0.35	0.37	0.71	[7]
Post states	1.00	0.98	0.98	0.71	0.88	1.00	[7]
Absolute AEs rates (%)
Diclofenac	21.30	0.14	0.07	0.06	0.09	0.02	[11]
Relative risk of AEs rate of different treatment strategies
Celecoxib vs. diclofenac	0.66	0.43	0.68	0.51	1.40	1.42	[9]
Imrecoxib vs. celecoxib	0.50	1.36	0.50	1.00	1.00	1.00	[16, 17]
Imrecoxib vs. diclofenac	0.33	0.58	0.34	0.51	1.40	1.42	–
Relative risk of AEs rate with the addition of a PPI
Diclofenac	0.43	0.37	0.46	1.00	1.00	1.00	[5]
imrecoxib	0.25	0.25	0.25	1.00	1.00	1.00	[5]

^aRMB exchange rate against the USD was 100:689.85 in 2019, and the consumer price index (CPI) was 101.4%, 102.0%, 101.6%, 102.1% and 102.9% in 2015, 2016, 2017, 2018, and 2019, respectively [20]. All the cost was adjusted to 2019 based on the exchange rate and CPI
^b The maintenance cost of symptomatic ulcer and complicated GI were calculated by multiplying the cost of initial state by the recurrence rate, the recurrence rate were 2.33%[21] and 1.59%[22] of symptomatic ulcer and complicated GI in each circle, respectively

ISSN: 1478-7547